Top news of the day across the health care landscape.
The risk of a solid subsequent malignant neoplasm is elevated in survivors of childhood Hodgkin lymphoma, according to an extended follow-up of more than 25 years.
Caplacizumab-yhdp (Cablivi, Sanofi) is a targeted treatment designed to inhibit the formation of blood clots in adults with acquired thrombotic thrombocytopenic purpura.
Data from 2 phase 3 trials showed significant improvement in disease activity in patients with moderate-to-severe atopic dermatitis treated with baricitinib (Olumiant).
Researchers at University of Texas Health Science Center at San Antonio studied 28,000 childhood cancer survivors to determine similarities in long-term effects for various chemotherapies.
Top news of the day across the health care landscape.
Injection drug use has been identified as a predominant risk factor for hepatitis C infection and the opioid epidemic has been suggested as a driver of a recent rise in infections.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.